Skip to main content

Table 8 Limitations of treatment success in first-line ER+, HER2- mBC patients - aromatase inhibitors only – from physician survey (n = 103)

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

  Not at all substantial Not at all substantial Moderately substantial Substantial Very substantial
  n % n % n % n % n %
Efficacy 4 3.9% 8 7.8% 43 41.8% 25 24.3% 23 22.3%
Safety/Tolerability 16 15.5% 24 23.3% 23 22.3% 29 28.2% 11 10.7%
Drug resistance 1 1.0% 12 11.7% 42 40.8% 41 39.8% 7 6.8%
Adherence 13 12.6% 23 22.3% 33 32.0% 24 23.3% 10 9.7%
Financial cost of treatments 14 13.6% 24 23.3% 28 27.2% 28 27.2% 9 8.7%
  1. mBC metastatic breast cancer